Abstract
INTRODUCTION: Chronic obstructive pulmonary disease (COPD) is a disease characterized by progressive poorly reversible airway destruction. Cardiovascular disease accounts for significant morbidity and mortality in chronic obstructive pulmonary disease (COPD). Its prevalence and mechanisms of association have not been elucidated. The study aimed to assess the prevalence of echocardiographic abnormalities and potential risk factors in patients with COPD.
MATERIALS AND METHODS: A total of 86 COPD patients were enrolled in the present study. All patients were subjected to full medical history and clinical examination, chest radiography, complete blood count, lipid profile, spirometry, 2D-echocardiography.
RESULTS: 86 patients included in our study. Out of 86 patients, 74( 86%) were male and 12 ( 14 %) were females. Male to female ratio was 6.1:1. Mean age was 58.2 ± 12.7 years. Severity of COPD patients classify according to GOLD criteria. Out of 86 patients, 15 patients had FEV1< 80% of predicted, 10% patients had mod.(FEV1 50-80 %), 24 had severe and 37 had very severe disease. Pulmonary artery hypertension was defined as SPAP> 30 mmHg which was seen in 40 cases (46.5%) . Out of 50 patients, 15 (17.4%) patients had mild, 5 (10.5%) had moderate and 18 (18.6%) had severe pulmonary hypertension, 12 (13.6%) patients had right ventricular systolic dysfunction, 11 (12.8%) had left ventricular systolic dysfunction and left ventricular hypertrophy. 16 ( 18.6%) had cor pulmonale.
CONCLUSION: Echocardiography is helpful in early detection of cardiac complication in COPD patients.
KEY WORDS: Chronic obstructive pulmonary disease , pulmonary hypertension, cor pulmonale, left ventricular hyperterophy.
References
1. Murray CJ, Lopez AD: Alternative projections of mortality and disability by cause 1990- 2020: Global Burden Disease Study. Lancet , 1997; 349: 1498-1504.
2. World Health Report, World Health Organization, Geneva. 2000.
3. Anthonisen N, Connett JE, Kiley JP, Altose MD, Bailey WC, et al. Effects of Smoking Intervention and the Use of an Inhaled Anticholinergic Bronchodilator on the Rate of Decline of FEV1. JAMA.1994;272:1497–1505
4. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, Global initiative for chronic obstructive pulmonary disease (GOLD), 2010.
5. Schmailzl KJG. Conventional Echocardio-graphy: Examination Procedure, Fundamental measurement and Assessment Tasks. In Schmailzl JG, Ormerod O, Editors. Ultrasound in Cardiology (1st ed.). Berlin: Blackwell Science 1994; 49-8.
6. Oh JK, Seward JB, Tajik AJ. The Echo Manual: the Mayo Clinic (13rd ed.). New Delhi: Lippincott Williams 2006; 7-28.
7. Chemla D, Castelain V, Humbert M, Simonneau JLHG, Lecarpentier Y, Hervé P. New Formula for Predicting Mean Pulmonary Artery Pressure Using Systolic Pulmonary Artery Pressure. Chest. 2004;126:1313–17.
8. Libby P, Bonow RO, Zipes DP, Mann DL, editors. 8 th. Philadelphia: Saunders; 2008. Braunwald’s Heart Disease; p. 251.
9. Weitzenblum E, Hirth C, Ducolone A, Mirhom R, Rasaholinjanahary J, Ehrhart M. Prognostic value of pulmonary artery pressure In chronic COPD. Thorax. 1981;36:752–8.
10. Weitzenblum E, Sautegeau A, Ehrhart M, Mammosser M, Hirth C, Roegel E. long term course of pulmonary artery pressure In chronic COPD. Am Rev Respir Dis. 1984;130:993–8.
11. Burrows B, Kettel LJ, Niden AH, Rabinowitz M, Diener CF. Patterns of cardiovascular dysfunction in COPD. N Engl J Med. 1972;286:912–8.
12. Fishman AP. State of the art: Chronic cor pulmonale. Am Rev Respir Dis. 1976;114:775–94.
13. Pietra G. Pathology of the pulmonary vasculature and heart. In: Cherniack N, editor. COPD. 1996. pp. 21–6.
14. Rigolin VH, Robiolio PA, Wilson JS, Harrison JK, Bashore TM. The forgotten chamber: The importance of the right ventricle. Cathet Cardiovasc Diagn. 1995;35:18–28.
15. Fishman AP. State of the art: Chronic Cor Pulmonale. Am Rev Respire Dis. 1976;114:775–94.
16. Murphy ML, Adamson J, Hutcheson F. Left ventricular hypertrophy in patients with chronic bronchitis and emphysema. Ann Intern Med. 1974;81:307–13.
17. Fluck DC, Chandrasekar RG, Gardner FV. Left ventricular hypertrophy in chronic bronchitis. Br Heart J.1966;28:92–7.
18. Render ML, Weinstein AS, Blaustein AS. Left ventricular dysfunction in deteriorating patients with chronic obstructive pulmonary disease. Chest. 1995;107:162–8.
19. Vizza CD, Lynch JP, Ochoa LL, Richardson G, Trulock EP. Right and left ventricular dysfunction in patients with severe pulmonary disease. Chest. 1998;113:576–83.
20. Jardin F, Gueret P, Prost JF, Farcot JC, Ozier Y, Bourdarias JP. Two-dimensional echocardiographic assessment of left ventricular function in chronic obstructive pulmonary disease. Am Rev Respir Dis.1984;129:135–42.
21. Louridas G, Patakas D, Stavropoulos C. Left ventricular function in patients with chronic obstructive pulmonary disease. Cardiology. 1981;67:73–80.
22. Poddar AK, Chakraborti BN, Ghosh JL, Nandy S, Hazra S. Assessment of left ventricular function in patients of COPD :Ind J Tub. 1997;44:181.
DOI: http://dx.doi.org/10.18535/jmscr/v4i6.77
